A Biomarker-Based Trial Assessing Association between Molecular Signatures and Treatment Response with Different Targeted Agents in Metastatic Gastric Cancer Patients : VIKTORY

Trial Profile

A Biomarker-Based Trial Assessing Association between Molecular Signatures and Treatment Response with Different Targeted Agents in Metastatic Gastric Cancer Patients : VIKTORY

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs AZD 5363 (Primary) ; AZD-1775 (Primary) ; Savolitinib (Primary) ; Selumetinib (Primary) ; Vistusertib (Primary) ; Docetaxel; Paclitaxel
  • Indications Gastric cancer
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms VIKTORY
  • Most Recent Events

    • 10 Jul 2017 New trial record
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top